New combo therapy for chronic heart failure

Entresto is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. More

POPULAR ON THE WEB

Top pharmacy stories of 2016

Where do pharmacists earn the least?

10 shocking things I've learned as a pharmacist

EDITOR'S CHOICE

Hospitals turn to RFID for medication replenishment

The RFID process helps eliminate the error-prone human factor associated with manually checking the trays. More

Inside The Latest Issue

This year's Top Drugs Remember When: The $4 generics battle was in full swing FDA approves lixisenatide for type 2 diabetes

December 30, 2016

Continuing education

Key cogs in the management of Parkinson's disease

Addressing unique medication adherence issues for patients with schizophrenia

Rheumatoid arthritis: Partnering for optimal care

Get the free app!

Part of the

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us